Reported 2 days ago
UroGen Pharma has received FDA approval for ZUSDURI, an innovative treatment for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This first-of-its-kind medication, previously known as UGN-102, delivers mitomycin via a sterile hydrogel using sustained-release technology. The approval comes after encouraging results from the Phase 3 ENVISION trial, which showed that 78% of patients achieved a complete response at three months, with a notable majority maintaining this response after 12 months.
Source: YAHOO